Clinical Trials Browser

Terminated × Breast Neoplasms × Interleukin-2 × Clear all

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Phase 1 Terminated

Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

Phase 1/2 Terminated

3 enrolled 14 charts

BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

NCT00784524 2019-06-06

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

Phase 2 Terminated

14 enrolled 8 charts

Breast Neoplasms

NCT00376805 2017-12-28

Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer

Phase 2 Terminated

6 enrolled 9 charts

Breast Neoplasms, Breast Neoplasms, Male